Release date: 2015-12-11

For Merck, the development company of the magical drug Keytruda, this will be an invaluable endorsement! It is the best Christmas gift! On December 6, 2015, major US media outlets reported on it, the 39th President of the United States, Jimmy Carter A statement issued on the 6th said that after the doctor had done the last brain magnetic resonance scan, he did not find melanoma or new cancer cells that had appeared in his brain.

President Carter was born on October 1, 1924. He served as the 39th President of the United States from 1977 to 1981 and won the Nobel Peace Prize in 2002. On August 20, 2015, at the press conference held at the Carter Center in Atlanta, Georgia, the 91-year-old former US President Jimmy Carter announced that he had diagnosed advanced melanoma and four tumors in his brain. 2 mm in size. When talking about terminal illness, President Carter is optimistic and calm, he jokingly said: "The two Presidents Bush have called me, as well as President Obama, Vice President, Secretary of State, President Clinton and Hillary Clinton - this is also a long time They called me for the first time." "I thought it only took a few weeks to survive, but I am surprisingly relaxed and ready for a new adventure!" President Carter announced that he will reduce his workload and focus on treatment. on. He also revealed that his treatment options include targeted radiotherapy and the new anti-cancer drug KEYTRUDA?.

KEYTRUDA? (pembrolizumab) was developed by Merck & Co., USA. On September 4, 2014, the US Food and Drug Administration (FDA) authorized the accelerated approval of Keytruda for the treatment of advanced or unresectable melanoma that no longer responds to others. Keytruda is the first approved drug in the United States to block the cellular pathway known as PD-1.

PD-1/PD-L1 immunotherapy is a new type of anti-cancer immunotherapy that is widely researched and studied worldwide. It aims to fully utilize the body's own immune system to resist and fight cancer by blocking PD. The -1/PD-L1 signaling pathway kills cancer cells and has the potential to treat multiple types of tumors, which is expected to substantially improve overall patient survival. Such attractive medical value and business prospects, the major pharmaceutical giants will never let go, the competition is unprecedentedly fierce! including Merck, Bristol-Myers Squibb, AstraZeneca, Roche. Melanoma is the preferred indication for attention. Bristol-Myers Squibb's PD-1 inhibitor Opdivo (nivolumab) was approved in Japan in July 2014, becoming the first PD-1 inhibitor approved worldwide; and Merck's Keytruda was approved by the FDA in early September 2014. The first PD-1 inhibitor approved by the United States. AstraZeneca and Roche's PD-L1 inhibitors are also in Phase III clinical. PD-1/PD-L1 immunotherapy can be used in other larger ranges of tumors, such as lung cancer. Clinical trials of monotherapy and combination therapy are in full swing to fully exploit the maximum clinical potential and value of this class of miracle drugs.

Source: Medsci

Tartary Buckwheat Tea

Buckwheat Tea,Organic Buckwheat Tea,Bitter Tartary Buckwheat Tea,Buckwheat Granules

Huantai Biotechnology Co., Ltd. , https://www.huantaifds.com